Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
Laia Montoliu‐Gaya, André Strydom, Kaj Blennow, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 16, pp. 3639-3639
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Diagnostic performance of plasma pTau217, pTau181, Aβ1-42 and Aβ1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
Javier Arranz, Nuole Zhu, Sara Rubio‐Guerra, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 34
Adapting prescribing criteria for amyloid‐targeted antibodies for adults with Down syndrome
Hampus Hillerstrom, Richard A. Fisher, Matthew P. Janicki, et al.
Alzheimer s & Dementia (2024) Vol. 20, Iss. 5, pp. 3649-3656
Open Access | Times Cited: 8
Cognitive and functional performance and plasma biomarkers of early Alzheimer's disease in Down syndrome
Emily K. Schworer, Benjamin L. Handen, Melissa Petersen, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2024) Vol. 16, Iss. 2
Open Access | Times Cited: 6
Role of tau deposition in early cognitive decline in Down syndrome
Sigan L. Hartley, Benjamin L. Handen, Dana Tudorascu, et al.
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 22
The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease
Kirsten L. Viola, Maíra A. Bicca, Adrian M. Bebenek, et al.
Frontiers in Neuroscience (2022) Vol. 15
Open Access | Times Cited: 20
Diagnostic performance of plasma pTau 217 , pTau 181 , Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease
Javier Arranz, Nuole Zhu, Sara Rubio‐Guerra, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 12
State‐of‐the‐art therapy for Down syndrome
Nicola Lorenzón, Juanluis Musoles‐Lleó, Federica Turrisi, et al.
Developmental Medicine & Child Neurology (2023) Vol. 65, Iss. 7, pp. 870-884
Closed Access | Times Cited: 11
Clinical and research application of fluid biomarkers in autosomal dominant Alzheimer's disease and Down syndrome
María Carmona‐Iragui, Antoinette O’Connor, Jorge J. Llibre‐Guerra, et al.
EBioMedicine (2024), pp. 105327-105327
Open Access | Times Cited: 4
Blood biomarkers in Down syndrome: Facilitating Alzheimer's disease detection and monitoring
Melissa Petersen, Lisi Flores Aguilar, Elizabeth Head, et al.
Alzheimer s & Dementia (2024) Vol. 21, Iss. 1
Open Access | Times Cited: 4
Diagnostic performance of plasma biomarkers for Alzheimer's disease using a fully automated platform: A real-world clinical study
Fausto Roveta, Elisa Rubino, Andrea Marcinnò, et al.
Journal of Alzheimer s Disease (2025)
Open Access
Human Models of Down Syndrome
Megan Jandy, Hao Hu, Yan Liu, et al.
(2025), pp. 233-267
Closed Access
Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome
Jacob Dohl, Zoe Treadwell, Christopher M. Norris, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 3
Open Access
Untangle the mystery behind DS-associated AD – Is APP the main protagonist?
Ajay Elangovan, Harysh Winster Suresh Babu, Mahalaxmi Iyer, et al.
Ageing Research Reviews (2023) Vol. 87, pp. 101930-101930
Closed Access | Times Cited: 10
Longitudinal investigation of gait and Alzheimer's disease in adults with Down syndrome
Ashlyn Barry, Jamie C. Peven, Benjamin L. Handen, et al.
Alzheimer s & Dementia (2025) Vol. 21, Iss. 4
Open Access
Epigenetic Biomarkers in Alzheimer's Disease: Diagnostic and Prognostic Relevance
Tapan Behl, Ashishkumar Kyada, R Roopashree, et al.
Ageing Research Reviews (2024) Vol. 102, pp. 102556-102556
Closed Access | Times Cited: 3
Intricacies of Aging and Down Syndrome
G. Kozlov, Claudio Franceschi, Maria V. Vedunova
Neuroscience & Biobehavioral Reviews (2024) Vol. 164, pp. 105794-105794
Closed Access | Times Cited: 2
Diagnostic performance of plasma Aβ1-42, Aβ1-40and pTau181in the LUMIPULSE automated platform for the detection of Alzheimer disease
Javier Arranz, Nuole Zhu, Sara Rubio‐Guerra, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Use of biomarkers in the diagnosis of Alzheimer’s disease in adults with intellectual disability
Aoife McFeely, Antoinette O’Connor, Seán Kennelly
The Lancet Healthy Longevity (2024), pp. 100639-100639
Open Access | Times Cited: 1
Plasma Concentrations of Neurofilament Light Chain Protein and Brain-Derived Neurotrophic Factor as Consistent Biomarkers of Cognitive Impairment in Alcohol Use Disorder
Nerea Requena-Ocaña, Pedro Araos, Pedro Jesús Serrano Castro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1183-1183
Open Access | Times Cited: 3
Biochemical Discrimination of the Down Syndrome-Related Metabolic and Oxidative/Nitrosative Stress Alterations from the Physiologic Age-Related Changes through the Targeted Metabolomic Analysis of Serum
Giacomo Lazzarino, Angela Maria Amorini, Renata Mangione, et al.
Antioxidants (2022) Vol. 11, Iss. 6, pp. 1208-1208
Open Access | Times Cited: 4
Aging in Down Syndrome: Latest Clinical Advances and Prospects
Alessandra Cadete Martini, Melissa J. Alldred, Ann‐Charlotte Granholm
Journal of Clinical Medicine (2021) Vol. 10, Iss. 21, pp. 5037-5037
Open Access | Times Cited: 4
WITHDRAWN: Intricacies of aging and down syndrome
G. Kozlov, Claudio Franceschi, Maria V. Vedunova
Aspects of Molecular Medicine (2024), pp. 100035-100035
Open Access
Exploring peripheral fluid biomarkers for early detection of Alzheimer’s disease in Down syndrome: A literature review
Charlotte Jacob, M. De Tollenaere, Hanane Kachar, et al.
Heliyon (2024), pp. e41445-e41445
Open Access
Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome
Victoria Fleming, Christy Hom, I. C. H. Clare, et al.
International review of research in developmental disabilities (2022), pp. 227-263
Open Access | Times Cited: 2
Commentary on Oeckl et al., “Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181”
Elizabeth Head, Henrik Zetterberg
Annals of Neurology (2022) Vol. 92, Iss. 1, pp. 3-5
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top